The inclusion of cognition in vascular risk factor clinical practice guidelines
Kenneth Rockwood1, Laura E Middleton2, Paige K Moorhouse1, Ingmar Skoog3, Sandra E Black41Department of Medicine, Dalhousie University, Halifax, NS, Canada; 2Department of Psychiatry, University of California, San Francisco, CA, USA; 3Institute of Neuropsychiatry, Sahlgrenska Acade...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ef3b7737119b432f8493b7ec18a3c868 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Kenneth Rockwood1, Laura E Middleton2, Paige K Moorhouse1, Ingmar Skoog3, Sandra E Black41Department of Medicine, Dalhousie University, Halifax, NS, Canada; 2Department of Psychiatry, University of California, San Francisco, CA, USA; 3Institute of Neuropsychiatry, Sahlgrenska Academy of Göteborg University, Göteborg, Västra Götaland, Sweden; 4Department of Medicine, University of Toronto, Toronto, ON, CanadaBackground: People with vascular risk factors are at increased risk for cognitive impairment as well as vascular disease. The objective of this study was to evaluate whether vascular risk factor clinical practice guidelines consider cognition as an outcome or in connection with treatment compliance.Methods: Articles from PubMed, EMBASE, and the Cochrane Library were assessed by at least two reviewers and were included if: (1) Either hypertension, high cholesterol, diabetes, or atrial fibrillation was targeted; (2) The guideline was directed at physicians; (3) Adult patients (aged 19 years or older) were targeted; and (4) The guideline was published in English. Of 91 guidelines, most were excluded because they were duplicates, older versions, or focused on single outcomes.Results: Of the 20 clinical practice guidelines that met inclusion criteria, five mentioned cognition. Of these five, four described potential treatment benefits but only two mentioned that cognition may affect compliance. No guidelines adequately described how to screen for cognitive impairment.Conclusion: Despite evidence that links cognitive impairment to vascular risk factors, only a minority of clinical practice guidelines for the treatment of vascular risk factors consider cognition as either an adverse outcome or as a factor to consider in treatment. Keywords: clinical practice guidelines, evidence-based medicine, vascular risk, cognition, target organ damage |
|---|